|
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer Clinical research trials and Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer. Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer  Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
For Condition: Leukemia,Lymphoma,adult solid tumor,small intestine cancer
Status: Completed
Sponsor(s): University of Texas , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without filgrastim in treating patients who have advanced cancer.
Details: OBJECTIVES: - Determine the maximum tolerated doses of a rebeccamycin analogue and cisplatin with or without filgrastim (G-CSF) in patients with advanced malignancies. - Determine the qualitative and quantitative toxicities of these regimens in these patients. - Determine if the pharmacokinetics of a rebeccamycin analogue are affected by cisplatin and if there are sequence dependent pharmacokinetic effects. - Assess any antitumor effects of this regimen in these patients. OUTLINE: This is a dose-escalation, multicenter study of a rebeccamycin analogue and cisplatin. - The first patient of each cohort receives cisplatin IV over 1 hour followed 2 hours later by a rebeccamycin analogue IV over 1 hour on day 1. The second patient in the same cohort receives the same drugs in the reverse order. The drug sequence for each additional patient within the same cohort is alternated with reference to the preceding patient. During each subsequent course, the study drugs are administered to each patient in the reverse order as compared to the prior course. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Dose escalation is initially performed without filgrastim (G-CSF). Cohorts of 4-6 patients receive escalating doses of a rebeccamycin analogue and cisplatin until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose at which less than 2 of 6 patients experience dose limiting toxicity (DLT). If 2 of the first 6 patients experience DLT, then dose escalation proceeds in combination with G-CSF treatment. Patients receive G-CSF subcutaneously daily beginning on day 2 and continuing until blood counts have recovered for 2 days or until approximately day 15. Cohorts of 4-6 patients receive escalating doses of a rebeccamycin analogue and cisplatin as above. The MTD is defined as above. - Part II (heavily pretreated patients): Heavily pretreated patients receive a rebeccamycin analogue and cisplatin starting at 2 dose levels preceding the MTD from part I. Patients are followed for at least 30 days. PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for phase I of this study within 1.5 years and a minimum of 2 patients will be accrued for phase II of the study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically proven advanced malignancy that is refractory to prior therapy or unlikely to benefit from standard therapy (e.g., chemotherapy, radiotherapy, and surgery) - Part I: Previously untreated OR minimally pretreated - Ineligible for part I and considered heavily pretreated if: - Prior radiotherapy to wide ports involving the pelvis or at least 25% of bone marrow - Greater than 6 courses of prior combination chemotherapy including alkylating agent - Prior nitrosoureas or mitomycin - Widespread bone metastases with bone marrow involvement by bone marrow biopsy (positive bilateral bone marrow biopsy for lymphoma patients) - Part II: Heavily pretreated as defined above - Measurable or evaluable disease PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Life expectancy: - At least 3 months Hematopoietic: - Absolute neutrophil count greater than 1,500/mm^3 - Hemoglobin greater than 9 mg/dL - Platelet count greater than 100,000/mm^3 Hepatic: - Bilirubin less than 1.5 mg/dL Renal: - Creatinine less than 1.5 mg/dL Cardiovascular: - No uncontrolled hypertension - No angina pectoris - No clinically significant, multifocal, uncontrolled cardiac dysrhythmias Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No active serious infection - No clinically severe peripheral neuropathy (grade 1 or worse) - No nonmalignant medical condition that would preclude compliance or increase risk of participation in study - No hypersensitivity to E. coli derived drug preparations PRIOR CONCURRENT THERAPY: Biologic therapy: - No other concurrent colony stimulating factors for prophylactic purposes Chemotherapy: - See Disease Characteristics - At least 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas and mitomycin) and recovered Endocrine therapy: - No chronic oral corticosteroids - No concurrent corticosteroids except as prophylactic antiemetic Radiotherapy: - See Disease Characteristics - At least 3 weeks since prior radiotherapy and recovered Surgery: - See Disease Characteristics Other: - At least 1 month since prior investigational agent - No prophylactic oral or IV antibiotics for neutropenia unless fever present - No other concurrent anticancer treatment or investigational agent
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LisaHammond, Study Chair, University of Texas
St. Luke's Lutheran Hospital
San Antonio, Texas, 78229
United States
Cancer Therapy and Research Center
San Antonio, Texas, 78229
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229-3900
United States
Additional Information:
Study ID Numbers: CDR0000067430; UTHSC-IDD-98-34,SACI-IDD-98-34,NCI-T98-0069
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004189
Other Lymphoma Studies:
1. ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
2. Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
3. Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
4. Phase I Study of Anti-Tac(Fv)-PE38 (LMB-2), a Recombinant Single-Chain Immunotoxin for Treatment of Tac-Expressing Malignancies
5. Donor Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Related Studies:
Other Lymphoma Clinical Trials
Other Texas Clinical Trials
Other San Antonio Clinical Trials
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
|
|
|
|
|
|
|
|
